These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25536927)

  • 1. A systematic review on cost effectiveness of HIV prevention interventions in the United States.
    Huang YL; Lasry A; Hutchinson AB; Sansom SL
    Appl Health Econ Health Policy; 2015 Apr; 13(2):149-56. PubMed ID: 25536927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of a community-level HIV risk reduction intervention for women living in low-income housing developments.
    Johnson-Masotti AP; Pinkerton SD; Sikkema KJ; Kelly JA; Wagstaff DA
    J Prim Prev; 2005 Jul; 26(4):345-62. PubMed ID: 15995803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review on the cost-effectiveness of public health interventions for HIV prevention in industrialized countries.
    Schrappe M; Lauterbach K
    AIDS; 1998; 12 Suppl A():S231-8. PubMed ID: 9633007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence.
    Creese A; Floyd K; Alban A; Guinness L
    Lancet; 2002 May; 359(9318):1635-43. PubMed ID: 12020523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring the cost effectiveness of HIV prevention interventions in the US: pitfalls and problems.
    Hellinger FJ
    Appl Health Econ Health Policy; 2015 Apr; 13(2):129-33. PubMed ID: 25724918
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of environmental-structural communication interventions for HIV prevention in the female sex industry in the Dominican Republic.
    Sweat M; Kerrigan D; Moreno L; Rosario S; Gomez B; Jerez H; Weiss E; Barrington C
    J Health Commun; 2006; 11 Suppl 2():123-42. PubMed ID: 17148102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Threshold analysis and programs for prevention of HIV infection.
    Holtgrave DR; Qualls NL
    Med Decis Making; 1995; 15(4):311-7. PubMed ID: 8544675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
    Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
    N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV prevention cost-effectiveness: a systematic review.
    Galárraga O; Colchero MA; Wamai RG; Bertozzi SM
    BMC Public Health; 2009 Nov; 9 Suppl 1(Suppl 1):S5. PubMed ID: 19922689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy.
    Hornberger J; Holodniy M; Robertus K; Winnike M; Gibson E; Verhulst E
    Med Decis Making; 2007; 27(6):789-821. PubMed ID: 18057191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.
    Holtgrave DR
    J Public Health Manag Pract; 2007; 13(3):239-43. PubMed ID: 17435490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV.
    Pinkerton SD; Holtgrave DR; Bloom FR
    AIDS; 1998 Jun; 12(9):1067-78. PubMed ID: 9662204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cost-Effectiveness Tool to Guide the Prioritization of Interventions for Rheumatic Fever and Rheumatic Heart Disease Control in African Nations.
    Watkins D; Lubinga SJ; Mayosi B; Babigumira JB
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004860. PubMed ID: 27512994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States.
    Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
    AIDS; 2004 Oct; 18(15):2065-73. PubMed ID: 15577628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India.
    Dandona L; Kumar SG; Kumar GA; Dandona R
    BMC Health Serv Res; 2010 May; 10():117. PubMed ID: 20459755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and consequences of the US Centers for Disease Control and Prevention's recommendations for opt-out HIV testing.
    Holtgrave DR
    PLoS Med; 2007 Jun; 4(6):e194. PubMed ID: 17564488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of HIV prevention programs.
    Holtgrave DR; Qualls NL; Graham JD
    Annu Rev Public Health; 1996; 17():467-88. PubMed ID: 8724236
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.